Flamma launches a $200 million investment campaign

Flamma, a pharmaceutical contract development and manufacturing firm based in Bergamo, Italy, has announced a three-year, $200 million investment program. The company says it will improve a manufacturing site it acquired in Bulciago, Italy, and expand manufacturing of active pharmaceutical ingredients (APIs) at its China location from 200 m³ to 400 m³. It will also add highly potent API manufacturing at its plant in Malvern, Pennsylvania, and technologies including flow chemistry at its headquarters. The company says the expansion supports a strategy of securing domestic supply chains with the ability to transfer projects in China to Europe while pursuing API production for the Chinese market in China.